Reviews Vagifem


No reviews yet.

Vagifem Drug Description
Vagifem®
(estradiol vaginal) Tablets
25µg

ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA.
Three independent, case controlled studies have reported an increased risk
of endometrial cancer in postmenopausal women exposed to exogenous estrogens
for more than one year. This risk was independent of the other known risk factors
for endometrial cancer. These studies are further supported by the finding that
incident rates of endometrial cancer have increased sharply since1969 in eight
different areas of the United States with population-based cancer-reporting
systems, an increase which may be related to the rapidly expanding use of estrogens
during the last decade.
The three case-controlled studies reported that the risk of endome-trial cancer
in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The
risk appears to depend on both duration of treatment and on estrogen dose. In
view of these findings, when estrogens are used for the treatment of menopausal
symptoms, the lowest dose that will control symptoms should be utilized and
medication should be discontinued as soon as possible. When prolonged treatment
is medically indicated, the patient should be reassessed, on at least a semi-annual
basis, to determine the need for continued therapy.
Close clinical surveillance of all women taking estrogens is important. In
all cases of undiagnosed persistent or reoccurring abnormal vaginal bleeding,
adequate diagnostic measures should be undertaken to rule out malignancy. There
is no evidence at present that "natural" estrogens are more or less
hazardous than "synthetic" estrogens at equi-estrogenic doses.

DRUG DESCRIPTION
VAGIFEM® (estradiol vaginal tablets) are small, white, film-coated tablets containing 25.8µg of estradiol hemihydrate equivalent to 25µg of estradiol.
Each tablet contains the following inactive ingredients: hypromellose, lactose monohydrate, maize starch and magnesium stearate. The film coating contains hypromellose and polyethylene glycol. Each white tablet is 6 mm in diameter and is placed in a disposable applicator. Each tablet-filled applicator is packaged separately in a blister pack. 17β-estradiol hemihydrate is a white, almost white or colorless crystalline solid, chemically described as estra-1,3,5 (10)-triene-3,17 diol.
The chemical formula is C18H24O2•½ H2O
with a molecular weight of 281.4.
The structural formula is:







Last reviewed on RxList: 7/25/2008




Vagifem Drug Description
Vagifem®
(estradiol vaginal) Tablets
25µg

ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA.
Three independent, case controlled studies have reported an increased risk
of endometrial cancer in postmenopausal women exposed to exogenous estrogens
for more than one year. This risk was independent of the other known risk factors
for endometrial cancer. These studies are further supported by the finding that
incident rates of endometrial cancer have increased sharply since1969 in eight
different areas of the United States with population-based cancer-reporting
systems, an increase which may be related to the rapidly expanding use of estrogens
during the last decade.
The three case-controlled studies reported that the risk of endome-trial cancer
in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The
risk appears to depend on both duration of treatment and on estrogen dose. In
view of these findings, when estrogens are used for the treatment of menopausal
symptoms, the lowest dose that will control symptoms should be utilized and
medication should be discontinued as soon as possible. When prolonged treatment
is medically indicated, the patient should be reassessed, on at least a semi-annual
basis, to determine the need for continued therapy.
Close clinical surveillance of all women taking estrogens is important. In
all cases of undiagnosed persistent or reoccurring abnormal vaginal bleeding,
adequate diagnostic measures should be undertaken to rule out malignancy. There
is no evidence at present that "natural" estrogens are more or less
hazardous than "synthetic" estrogens at equi-estrogenic doses.

DRUG DESCRIPTION
VAGIFEM® (estradiol vaginal tablets) are small, white, film-coated tablets containing 25.8µg of estradiol hemihydrate equivalent to 25µg of estradiol.
Each tablet contains the following inactive ingredients: hypromellose, lactose monohydrate, maize starch and magnesium stearate. The film coating contains hypromellose and polyethylene glycol. Each white tablet is 6 mm in diameter and is placed in a disposable applicator. Each tablet-filled applicator is packaged separately in a blister pack. 17β-estradiol hemihydrate is a white, almost white or colorless crystalline solid, chemically described as estra-1,3,5 (10)-triene-3,17 diol.
The chemical formula is C18H24O2•½ H2O
with a molecular weight of 281.4.
The structural formula is:







Last reviewed on RxList: 7/25/2008




Vagifem Drug Description
Vagifem®
(estradiol vaginal) Tablets
25µg

ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA.
Three independent, case controlled studies have reported an increased risk
of endometrial cancer in postmenopausal women exposed to exogenous estrogens
for more than one year. This risk was independent of the other known risk factors
for endometrial cancer. These studies are further supported by the finding that
incident rates of endometrial cancer have increased sharply since1969 in eight
different areas of the United States with population-based cancer-reporting
systems, an increase which may be related to the rapidly expanding use of estrogens
during the last decade.
The three case-controlled studies reported that the risk of endome-trial cancer
in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The
risk appears to depend on both duration of treatment and on estrogen dose. In
view of these findings, when estrogens are used for the treatment of menopausal
symptoms, the lowest dose that will control symptoms should be utilized and
medication should be discontinued as soon as possible. When prolonged treatment
is medically indicated, the patient should be reassessed, on at least a semi-annual
basis, to determine the need for continued therapy.
Close clinical surveillance of all women taking estrogens is important. In
all cases of undiagnosed persistent or reoccurring abnormal vaginal bleeding,
adequate diagnostic measures should be undertaken to rule out malignancy. There
is no evidence at present that "natural" estrogens are more or less
hazardous than "synthetic" estrogens at equi-estrogenic doses.

DRUG DESCRIPTION
VAGIFEM® (estradiol vaginal tablets) are small, white, film-coated tablets containing 25.8µg of estradiol hemihydrate equivalent to 25µg of estradiol.
Each tablet contains the following inactive ingredients: hypromellose, lactose monohydrate, maize starch and magnesium stearate. The film coating contains hypromellose and polyethylene glycol. Each white tablet is 6 mm in diameter and is placed in a disposable applicator. Each tablet-filled applicator is packaged separately in a blister pack. 17β-estradiol hemihydrate is a white, almost white or colorless crystalline solid, chemically described as estra-1,3,5 (10)-triene-3,17 diol.
The chemical formula is C18H24O2•½ H2O
with a molecular weight of 281.4.
The structural formula is:







Last reviewed on RxList: 7/25/2008




Vagifem Drug Description
Vagifem®
(estradiol vaginal) Tablets
25µg

ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA.
Three independent, case controlled studies have reported an increased risk
of endometrial cancer in postmenopausal women exposed to exogenous estrogens
for more than one year. This risk was independent of the other known risk factors
for endometrial cancer. These studies are further supported by the finding that
incident rates of endometrial cancer have increased sharply since1969 in eight
different areas of the United States with population-based cancer-reporting
systems, an increase which may be related to the rapidly expanding use of estrogens
during the last decade.
The three case-controlled studies reported that the risk of endome-trial cancer
in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The
risk appears to depend on both duration of treatment and on estrogen dose. In
view of these findings, when estrogens are used for the treatment of menopausal
symptoms, the lowest dose that will control symptoms should be utilized and
medication should be discontinued as soon as possible. When prolonged treatment
is medically indicated, the patient should be reassessed, on at least a semi-annual
basis, to determine the need for continued therapy.
Close clinical surveillance of all women taking estrogens is important. In
all cases of undiagnosed persistent or reoccurring abnormal vaginal bleeding,
adequate diagnostic measures should be undertaken to rule out malignancy. There
is no evidence at present that "natural" estrogens are more or less
hazardous than "synthetic" estrogens at equi-estrogenic doses.

DRUG DESCRIPTION
VAGIFEM® (estradiol vaginal tablets) are small, white, film-coated tablets containing 25.8µg of estradiol hemihydrate equivalent to 25µg of estradiol.
Each tablet contains the following inactive ingredients: hypromellose, lactose monohydrate, maize starch and magnesium stearate. The film coating contains hypromellose and polyethylene glycol. Each white tablet is 6 mm in diameter and is placed in a disposable applicator. Each tablet-filled applicator is packaged separately in a blister pack. 17β-estradiol hemihydrate is a white, almost white or colorless crystalline solid, chemically described as estra-1,3,5 (10)-triene-3,17 diol.
The chemical formula is C18H24O2•½ H2O
with a molecular weight of 281.4.
The structural formula is:







Last reviewed on RxList: 7/25/2008




Vagifem Drug Description
Vagifem®
(estradiol vaginal) Tablets
25µg

ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA.
Three independent, case controlled studies have reported an increased risk
of endometrial cancer in postmenopausal women exposed to exogenous estrogens
for more than one year. This risk was independent of the other known risk factors
for endometrial cancer. These studies are further supported by the finding that
incident rates of endometrial cancer have increased sharply since1969 in eight
different areas of the United States with population-based cancer-reporting
systems, an increase which may be related to the rapidly expanding use of estrogens
during the last decade.
The three case-controlled studies reported that the risk of endome-trial cancer
in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The
risk appears to depend on both duration of treatment and on estrogen dose. In
view of these findings, when estrogens are used for the treatment of menopausal
symptoms, the lowest dose that will control symptoms should be utilized and
medication should be discontinued as soon as possible. When prolonged treatment
is medically indicated, the patient should be reassessed, on at least a semi-annual
basis, to determine the need for continued therapy.
Close clinical surveillance of all women taking estrogens is important. In
all cases of undiagnosed persistent or reoccurring abnormal vaginal bleeding,
adequate diagnostic measures should be undertaken to rule out malignancy. There
is no evidence at present that "natural" estrogens are more or less
hazardous than "synthetic" estrogens at equi-estrogenic doses.

DRUG DESCRIPTION
VAGIFEM® (estradiol vaginal tablets) are small, white, film-coated tablets containing 25.8µg of estradiol hemihydrate equivalent to 25µg of estradiol.
Each tablet contains the following inactive ingredients: hypromellose, lactose monohydrate, maize starch and magnesium stearate. The film coating contains hypromellose and polyethylene glycol. Each white tablet is 6 mm in diameter and is placed in a disposable applicator. Each tablet-filled applicator is packaged separately in a blister pack. 17β-estradiol hemihydrate is a white, almost white or colorless crystalline solid, chemically described as estra-1,3,5 (10)-triene-3,17 diol.
The chemical formula is C18H24O2•½ H2O
with a molecular weight of 281.4.
The structural formula is:







Last reviewed on RxList: 7/25/2008





Other reviews about Vagifem on wordpress

Vaginal Dryness Medications May Affect Breast Cancer Treatment
  by Rachel
A very small study published in the journal Annals of Oncology [pre-print article available for free as PDF] suggested that a particular drug for vaginal dryness (Vagifem) may […]


Ask Dr. Pat: Sex and the Safety of Vagifem
  by nichirei
Have a question about women's health or menopause? Dr. Patricia Yarberry Allen may have the answer. Click here to send in your question to be posted on WVFC. Question: […]


Viva Viagra?
  by terrymarotta
OK, you want to know why we resent you guys? We resent you because all the best creativity gets directed to your needs instead of ours. Take the […]


Vagina Dialogues, Part Two: Guest Blog from a Satisfied 62-Year-Old
  by nichirei
I have always enjoyed sex – as  a single woman and then as a happily married woman.  Over the years, as my love for my husband deepened, making […]


ESTRING® (estradiol) Vaginal Ring
  by kanlayanee
[caption id="" align="alignnone" width="288" caption="ESTRING 2 MG VAGINAL RING PHARMACIA/UPJHN Approx. Price: $167.24 per 1Each"][/caption] Adult Min/Max Dose: 7.5mcgAll insert 1 vaginal ring by […]


Vagifem
  by trumedcanada
Vagifem is a prescription drug that has been proved to be extremely effective to relieve the discomfort associated with menopausal atrophic vaginitis by treating vaginal estrogen deficiency. It […]


Ordering Medications from Canada
  by ysfried
I have a patient who ordered her Vagifem tablets from http://www.northwestpharmacy.com/ and they cost $74.49 for 45 tablets. Her cost from her US pharmacy/Insurance was $56 for […]


Watching my ex's April Fool's Birthday--from afar!
  by Ken Besseder
K turns 58 and I revist the old haunts By Ken Besseder, author of 50 Ways to Lick Your Lover http://tiny.cc/hyxtb (Get it at www.amazon.com) It’s K’s Birthday today (she’s the […]


Q: Is Vagifem good for dryness?
  by barbdepree
Vagifem is a low-dose ‘localized’ estrogen. It is delivering estrogen to the vagina and adjacent tissues, but not to areas outside of this area (that's why it's called […]


Chicks Without Ovaries -- a Maintenance Plan
  by jujuridl
Ovaries. You can’t always live with them — I know I couldn’t — but when they’re gone, there are things we miss. I surely don't miss the troublesome little […]



Other reviews about Vagifem on web:

Patient and prescribing information from Novo Nordisk. Includes information about menopause, atrophic vaginitis and resources. Vagifem Estradiol | Estrogen Therapy for Atrophic Vaginitis


Accurate, FDA approved Vagifem information for healthcare professionals and patients - brought to you by Drugs.com. Vagifem Official FDA information, side effects and uses.


All about Vagifem Tablets. View complete and up to date Vagifem information - part of the Drugs.com trusted medication database. Vagifem Tablets Facts and Comparisons at Drugs.com


Learn about the prescription medication Vagifem (Estradiol Vaginal Tablets), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Vagifem (Estradiol Vaginal Tablets) Drug Information: Uses, Side ...


Find patient medical information for Vagifem Vagl on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Vagifem Vagl : Uses, Side Effects, Interactions, Pictures ...


Buy Vagifem (Estradiol) from our Canadian Online Pharmacy by calling 1-877-888-3562. Fully licensed, fast delivery, free doctor consultation provided. Buy Vagifem (Estradiol) Online Now


Vagifem is a prescription estrogen medication that helps relieve vaginal problems due to menopause. This eMedTV article takes a closer look at Vagifem, including information on how ... Vagifem


Vagifem is a female hormone and is usually given to women who do not produce the proper amount. Side effects and interactions are available at drugstore.com; plus get home delivery ... Vagifem - drugstore.com. Low prices, side effects, interactions.


Sign Up Now. Vagifem ® 10 mcg is an estrogen (estradiol) indicated for the treatment of atrophic vaginitis due to menopause. It effectively relieves the most bothersome symptoms of ... Vagifem


Vagifem Side Effects: abdominal pain, abdominal pain lower, angioedema. Vagifem Reports: patient, 54 years of age, was treated with Vagifem.. Vagifem Reviews: Dear El, I also ... Vagifem Side Effects





Featured Reviews

Reviews Apriso

Apriso Drug Description APRISO™ (mesalamine) Extended-Release Capsules DRUG DESCRIPTION What are the possible side effects of mesalamine oral (Apriso, Asacol, Lialda, Pentasa)? Get emergency medical help if you have any of...
Read More  |  Review This
Reviews Avodart

Avodart Drug Description AVODART (dutasteride) Soft Gelatin Capsules DRUG DESCRIPTION What are the possible side effects of dutasteride (Avodart)? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Reviews Podofilox Topical Solution

Podofilox Topical Solution Drug Description Podofilox Topical Solution 0.5% DRUG DESCRIPTION Podofilox Topical Solution is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae...
Read More  |  Review This
Reviews Oforta

Oforta Drug Description Oforta™ (fludarabine phosphate) Tablets for Oral Use. WARNING: CNS TOXICITY, HEMOLYTIC ANEMIA, AND PULMONARY TOXICITY Severe neurologic effects, including blindness, coma, and death were observed in...
Read More  |  Review This
Reviews Atropine

Atropine Drug Description DRUG DESCRIPTION ATROPINE SULFATE Injection, USP 0.1 mg/mI (Adult) 0.05 mg/mL (Pediatric) ABBOJECT® Unit of Use Syringe Atropine Sulfate Injection, USP is a sterile, nonpyrogenic isotonic solution of atropine...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....